Fig. 2From: Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edemaTornado diagram ranibizumab PRN vs aflibercept. RR relative risk; OR odds ratio; BCVA best corrected visual acuity; NMB net monetary benefit; BSE better-seeing eye; WSE worse-seeing eye; DME diabetic macular edemaBack to article page